Brooks Laboratories Ltd. (NSE: BROOKS) and Indegene Ltd (NSE: INDGN) are both listed in the Life Sciences Tools and Services industry. Brooks Laboratories has a market capitalisation of ₹187 Cr and Indegene ₹14,921 Cr, as of 9 Nov 2026. Their P/E ratios are 7.6 and 37.3 respectively. Return on equity is 22.28% for Brooks Laboratories and 13.94% for Indegene. Over one year, Brooks Laboratories's share price is down 40.7% and Indegene's is up 14.6%.
| Metric | Brooks Laboratories | Indegene |
|---|---|---|
| NSE Symbol | BROOKS | INDGN |
| BSE Code | 533543 | 544172 |
| Share Price | ₹65.70 | ₹614.50 |
| Market Cap | ₹187 Cr | ₹14,921 Cr |
| P/E Ratio | 7.6 | 37.3 |
| Return on Equity | 22.28% | 13.94% |
| Return on Assets | 2.77% | 7.82% |
| Dividend Yield | — | 0.36% |
| Beta (1Y) | 1.19 | 0.45 |
| 1-Year Price Change | -40.7% | +14.6% |
| 3-Month Price Change | +9.8% | +8.0% |
| 52-Week Range | ₹36.30 – ₹112.40 | ₹414.00 – ₹638.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹19 Cr | ₹1,122 Cr |
| Quarterly Net Profit | ₹68 Cr | ₹112 Cr |
| Net Margin | 351.2% | 10.0% |
| EPS (Basic, Quarter) | ₹22.95 | ₹4.67 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding an…
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, tech…
Indegene has a market capitalisation of ₹14,921 Cr, against ₹187 Cr for Brooks Laboratories as of 9 Nov 2026, about 79.8 times the size by market cap.
Brooks Laboratories has a P/E of 7.6 and Indegene a P/E of 37.3 as of 9 Nov 2026.
Brooks Laboratories has a return on equity of 22.28% and Indegene 13.94%.
Brooks Laboratories's share price is down 40.7% over one year and Indegene's is up 14.6%.
Brooks Laboratories reported revenue of ₹19 Cr and net profit of ₹68 Cr for Q2 FY27. Indegene reported revenue of ₹1,122 Cr and net profit of ₹112 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.